| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +214K | 100% | $7.00 | +$1.5M |
| Sells | 0 | ||||
| Net | +3 | +214K | 100% | +$1.5M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Leslie W. Kreis | Director, 10%+ Owner | $93.5M | +$500K | +0.54% | Jun 27, 2025 |
| Bios Equity COF, LP | Director, 10%+ Owner | $93.5M | +$500K | +0.54% | Jun 27, 2025 |
| Aaron G.L. Fletcher | Director, 10%+ Owner | $93.5M | +$500K | +0.54% | Jun 27, 2025 |
| Todd S. Thomson | Director, 10%+ Owner | $13.9M | May 22, 2025 | ||
| Daniel M. Schmitt | President, CEO and Director, Director | $3.32M | Apr 1, 2025 | ||
| Bios Clinical Opportunity Fund, LP | 10%+ Owner | $1.22M | Aug 12, 2024 | ||
| Andrew Paul Mazar | Chief Operating Officer | $671K | Apr 1, 2025 | ||
| Bios 2024 Co-Invest, LP | Director, Member of 10% Group | $659K | Aug 14, 2024 | ||
| Dan Zabrowski | Director | $402K | May 22, 2025 | ||
| Amy L. Ronneberg | Director | May 22, 2025 | |||
| Roger Sawhney | Director | May 22, 2025 | |||
| Jason A. Keyes | Director | May 22, 2025 | |||
| Paul Lytle | Chief Financial Officer | Apr 1, 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|